Your SlideShare is downloading. ×
0
Endometriosis Industry - Current & Future Analysis of Market Competition
Endometriosis Industry - Current & Future Analysis of Market Competition
Endometriosis Industry - Current & Future Analysis of Market Competition
Endometriosis Industry - Current & Future Analysis of Market Competition
Endometriosis Industry - Current & Future Analysis of Market Competition
Endometriosis Industry - Current & Future Analysis of Market Competition
Endometriosis Industry - Current & Future Analysis of Market Competition
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

Endometriosis Industry - Current & Future Analysis of Market Competition

51

Published on

The report “OpportunityAnalyzer: Endometriosis – Opportunity Analysis and Forecasts to 2017″ by GlobalData is now available at RnRMarketResearch.com. Contact sales@rnrmarketresearch.com with …

The report “OpportunityAnalyzer: Endometriosis – Opportunity Analysis and Forecasts to 2017″ by GlobalData is now available at RnRMarketResearch.com. Contact sales@rnrmarketresearch.com with OpportunityAnalyzer: Endometriosis – Opportunity Analysis and Forecasts to 2017 in subject line and your contact details to purchase this report or get your questions answered.
Endometriosis is a gynecological disorder affecting women of childbearing age. This inflammatory condition is characterized by the growth of endometrial tissues outside of the uterus, and can cause chronic painful menstruation, painful intercourse, and infertility. For many women, endometriosis-associated pain can be so debilitating that it affects their ability to perform daily functions and significantly deters their quality of life.
The KOL’s agree patients with endometriosis have significant unmet needs due to the lack of approved treatment options that have both continuous efficacy and a favorable long-term safety profiles. Although the KOLs are optimistic about the potential approval of GnRH antagonists, they still foresee that unmet needs will persist. Being orally active is a major benefit for GnRH antagonists. As such research foresees they will rapidly shift market share away from GnRH agonists. However their price will limit penetration in other patient segments. Ultimately, since none of the marketed, off-label, or pipeline drugs are curative, significant opportunity will remain for safe, efficacious therapies that target the root cause of the condition.
In 2012, the global market was largely dominated by the US, with sales of $1.1bn. Combined sales in the 5EU were estimated to be $137.6m. By 2017, Research forecasts global endometriosis therapeutics sales to grow slowly to $1.2bn at a compound annual growth rate (CAGR) of 0.19%.
Highlights
Key Questions Answered
The endometriosis therapeutics market has had weak competition due to a lack of approved therapies, and high rates of off-label drug use. What are the underlying unmet needs in this market? What opportunities will remain after elagolix is launched?
The late-stage pipeline is comprised of GnRH antagonists. What sort of impact will these therapies have on this market? Which will emerge as market leaders? How will these products fare against existing therapies?
Complete Report Available @ http://www.rnrmarketresearch.com/opportunityanalyzer-endometriosis-opportunity-analysis-and-forecasts-to-2017-market-report.html .
The endometriosis therapeutics market has considerable unmet needs due to low diagnosis rates, minimal disease awareness, and lack of a well-tolerated long-term treatment options. Which drivers and barriers will affect the market landscape? What trends can be expected in each of US and 5EU?

Published in: Health & Medicine, Business
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
51
On Slideshare
0
From Embeds
0
Number of Embeds
1
Actions
Shares
0
Downloads
2
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. OpportunityAnalyzer: Endometriosis – Opportunity Analysis and Forecasts to 2017 by GlobalData Explore all reports for “ Women's Health Therapeutics ” market @ http://www.rnrmarketresearch.com/reports/lifesciences/pharmaceuticals/therapeutics/womens-healththerapeutics . © RnRMarketResearch.com ; sales@rnrmarketresearch.com ; +1 888 391 5441
  • 2. OpportunityAnalyzer: Endometriosis – Opportunity Analysis and Forecasts to 2017 Endometriosis is a gynecological disorder affecting women of childbearing age. This inflammatory condition is characterized by the growth of endometrial tissues outside of the uterus, and can cause chronic painful menstruation, painful intercourse, and infertility. For many women, endometriosisassociated pain can be so debilitating that it affects their ability to perform daily functions and significantly deters their quality of life. The KOL’s agree patients with endometriosis have significant unmet needs due to the lack of approved treatment options that have both continuous efficacy and a favorable long-term safety profiles. Although the KOLs are optimistic about the potential approval of GnRH antagonists, they still foresee that unmet needs will persist. Being orally active is a major benefit for GnRH antagonists. As such research foresees they will rapidly shift market share away from GnRH agonists. However their price will limit penetration in other patient segments. Ultimately, since none of the marketed, off-label, or pipeline drugs are curative, significant opportunity will remain for safe, efficacious therapies that target the root cause of the condition. In 2012, the global market was largely dominated by the US, with sales of $1.1bn. Combined sales in the 5EU were estimated to be $137.6m. By 2017, Research forecasts global endometriosis therapeutics sales to grow slowly to $1.2bn at a compound annual growth rate (CAGR) of 0.19%. Inquire for Discount @ http://www.rnrmarketresearch.com/contacts/discount?rname=146887 . © RnRMarketResearch.com ; sales@rnrmarketresearch.com ; +1 888 391 5441
  • 3. OpportunityAnalyzer: Endometriosis – Opportunity Analysis and Forecasts to 2017 Highlights Key Questions Answered The endometriosis therapeutics market has had weak competition due to a lack of approved therapies, and high rates of off-label drug use. What are the underlying unmet needs in this market? What opportunities will remain after elagolix is launched? The late-stage pipeline is comprised of GnRH antagonists. What sort of impact will these therapies have on this market? Which will emerge as market leaders? How will these products fare against existing therapies? The endometriosis therapeutics market has considerable unmet needs due to low diagnosis rates, minimal disease awareness, and lack of a well-tolerated long-term treatment options. Which drivers and barriers will affect the market landscape? What trends can be expected in each of US and 5EU? Complete Report Available @ http://www.rnrmarketresearch.com/opportunityanalyzer-endometriosis-opportunityanalysis-and-forecasts-to-2017-market-report.html . © RnRMarketResearch.com ; sales@rnrmarketresearch.com ; +1 888 391 5441
  • 4. OpportunityAnalyzer: Endometriosis – Opportunity Analysis and Forecasts to 2017 Key Findings •The single most important driver of growth will be the launch of novel agents with superior safety and more convenient oral formulations •GnRH agonists will rapidly shift market share from GnRH agonists however their price will limit penetration in other patient share segments •Incomplete knowledge regarding disease pathogenesis and pathophysiology creates a major obstacle in the development of novel therapeutics •Ultimately, since none of the marketed, off-label, and pipeline drugs are curative, significant opportunity will remain for safe, efficacious therapies that target the root cause of the condition. Scope •Overview of endometriosis, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines. •Annualized endometriosis therapeutics market revenue, annual cost of therapy, and top line US and 5EU market forecasts from 2012 to 2017. Buy a copy of report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=146887 . © RnRMarketResearch.com ; sales@rnrmarketresearch.com ; +1 888 391 5441
  • 5. OpportunityAnalyzer: Endometriosis – Opportunity Analysis and Forecasts to 2017 •Key topics covered include: strategic competitor assessment, market characterization, unmet needs, and implications for the endometriosis therapeutics market. •Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs. •Analysis of the current and future market competition in the global endometriosis therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications. Reasons to buy •Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list. •Develop business strategies by understanding the trends shaping and driving the global endometriosis therapeutics market. Buy a copy of report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=146887 . © RnRMarketResearch.com ; sales@rnrmarketresearch.com ; +1 888 391 5441
  • 6. OpportunityAnalyzer: Endometriosis – Opportunity Analysis and Forecasts to 2017 •Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors. •Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage. •Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global endometriosis therapeutics market in future. •Track drug sales in the global endometriosis therapeutics market from 2012-2017. •Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships. Complete Report Available @ http://www.rnrmarketresearch.com/opportunityanalyzer-endometriosis-opportunityanalysis-and-forecasts-to-2017-market-report.html . © RnRMarketResearch.com ; sales@rnrmarketresearch.com ; +1 888 391 5441
  • 7. OpportunityAnalyzer: Endometriosis – Opportunity Analysis and Forecasts to 2017 For more details contact Mr. Priyank Tiwari: sales@rnrmarketresearch.com / +18883915441 RnR Market Research RnRMarketResearch.com, an online repository of market research reports, offers in-depth analysis of over 5000 market segments. RnR Market Research library has syndicated reports by leading market research publishers across the globe. © RnRMarketResearch.com ; sales@rnrmarketresearch.com ; +1 888 391 5441

×